Royalty Pharma plc Payments to Acquire Finance Receivables
Royalty Pharma plc (RPRX) reported Payments to Acquire Finance Receivables of $703.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireFinanceReceivables · last filed 2026-08-05
- Royalty Pharma plc payments to acquire finance receivables for the quarter ending 2026-06-30 was $251.02M, a 22433.30% increase year-over-year.
- Royalty Pharma plc payments to acquire finance receivables for the quarter ending 2026-03-31 was $452.37M, a 42697.16% increase year-over-year.
- Royalty Pharma plc payments to acquire finance receivables for the quarter ending 2025-12-31 was $733.68M, a 47.80% increase year-over-year.
- Royalty Pharma plc payments to acquire finance receivables for the quarter ending 2025-09-30 was $961.87M, a 19.48% decline year-over-year.
- Royalty Pharma plc payments to acquire finance receivables for fiscal 2025 was $1.70B, a 32.25% decline from fiscal 2024.
- Royalty Pharma plc payments to acquire finance receivables for fiscal 2024 was $2.51B, a 18.44% increase from fiscal 2023.
- Royalty Pharma plc payments to acquire finance receivables for fiscal 2023 was $2.12B, a 21.47% increase from fiscal 2022.
- Royalty Pharma plc payments to acquire finance receivables for fiscal 2022 was $1.74B, a 20.53% decline from fiscal 2021.
| Period end | Payments to Acquire Finance Receivables 3 month | Payments to Acquire Finance Receivables 6 month | Payments to Acquire Finance Receivables 9 month | Payments to Acquire Finance Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | $251.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $703.39M 10-Q · filed 2026-08-05 | $1.44B derived: sum of 3 quarters · filed 2026-08-05 | $2.40B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $452.37M 10-Q · filed 2026-05-06 | $1.19B derived: sum of 2 quarters · filed 2026-05-06 | $2.15B derived: sum of 3 quarters · filed 2026-05-06 | $2.15B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $733.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.70B derived: sum of 2 quarters · filed 2026-02-11 | $1.70B derived: sum of 3 quarters · filed 2026-08-05 | $1.70B 10-K · filed 2026-02-11 |
| 2025-09-30 | $961.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $962.99M derived: sum of 2 quarters · filed 2026-08-05 | $964.04M 10-Q · filed 2025-11-05 | $1.46B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.17M 10-Q · filed 2026-08-05 | $498.59M derived: sum of 3 quarters · filed 2026-08-05 | $1.69B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.06M 10-Q · filed 2026-05-06 | $497.48M derived: sum of 2 quarters · filed 2026-05-06 | $1.69B derived: sum of 3 quarters · filed 2026-05-06 | $2.42B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $496.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.69B derived: sum of 2 quarters · filed 2026-02-11 | $2.42B derived: sum of 3 quarters · filed 2026-02-11 | $2.51B 10-K · filed 2026-02-11 |
| 2024-09-30 | $1.19B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.92B derived: sum of 2 quarters · filed 2025-11-05 | $2.01B 10-Q · filed 2025-11-05 | $3.01B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $728.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $814.71M 10-Q · filed 2025-08-06 | $1.82B derived: sum of 3 quarters · filed 2026-02-11 | $2.27B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $86.08M 10-Q · filed 2025-05-08 | $1.09B derived: sum of 2 quarters · filed 2026-02-11 | $1.54B derived: sum of 3 quarters · filed 2026-02-11 | $1.60B derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $1.00B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.45B derived: sum of 2 quarters · filed 2026-02-11 | $1.51B derived: sum of 3 quarters · filed 2026-02-11 | $2.12B 10-K · filed 2026-02-11 |
| 2023-09-30 | $451.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $511.58M derived: sum of 2 quarters · filed 2024-11-06 | $1.11B 10-Q · filed 2024-11-06 | $1.36B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $60.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $662.15M 10-Q · filed 2024-08-08 | $912.39M derived: sum of 3 quarters · filed 2025-02-12 | $2.23B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $601.71M 10-Q · filed 2024-05-09 | $851.95M derived: sum of 2 quarters · filed 2025-02-12 | $2.17B derived: sum of 3 quarters · filed 2025-02-12 | $2.34B derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $250.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $1.57B derived: sum of 2 quarters · filed 2025-02-12 | $1.74B derived: sum of 3 quarters · filed 2025-02-12 | $1.74B 10-K · filed 2025-02-12 |
| 2022-09-30 | $1.32B derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.49B derived: sum of 2 quarters · filed 2023-11-08 | $1.49B 10-Q · filed 2023-11-08 | $1.66B derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $175.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $175.09M 10-Q · filed 2023-08-08 | $346.83M derived: sum of 3 quarters · filed 2024-02-15 | $1.68B derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $85.00K 10-Q · filed 2023-05-09 | $171.82M derived: sum of 2 quarters · filed 2024-02-15 | $1.51B derived: sum of 3 quarters · filed 2024-02-15 | $1.69B derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $171.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $1.51B derived: sum of 2 quarters · filed 2024-02-15 | $1.69B derived: sum of 3 quarters · filed 2024-02-15 | $2.19B 10-K · filed 2024-02-15 |
| 2021-09-30 | $1.34B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.52B derived: sum of 2 quarters · filed 2022-11-08 | $2.02B 10-Q · filed 2022-11-08 | $2.82B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $180.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $683.74M 10-Q · filed 2022-08-04 | $1.49B derived: sum of 3 quarters · filed 2023-02-15 | $2.29B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $503.07M 10-Q · filed 2022-05-05 | $1.31B derived: sum of 2 quarters · filed 2023-02-15 | $2.11B derived: sum of 3 quarters · filed 2023-02-15 | $2.59B derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $805.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $1.61B derived: sum of 2 quarters · filed 2023-02-15 | $2.08B derived: sum of 3 quarters · filed 2023-02-15 | $2.18B 10-K · filed 2023-02-15 |
| 2020-09-30 | $802.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.28B derived: sum of 2 quarters · filed 2021-11-10 | $1.38B 10-Q · filed 2021-11-10 | $1.84B derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $475.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $574.62M 10-Q · filed 2021-08-11 | $1.04B derived: sum of 3 quarters · filed 2022-02-15 | $1.06B derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $99.29M 10-Q · filed 2021-05-11 | $566.06M derived: sum of 2 quarters · filed 2022-02-15 | $588.85M derived: sum of 3 quarters · filed 2022-02-15 | |
| 2019-12-31 | $466.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $489.56M derived: sum of 2 quarters · filed 2022-02-15 | $1.72B 10-K · filed 2022-02-15 | |
| 2019-09-30 | $22.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.25B 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $1.23B 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $269.59M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |